查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842329

美国次世代定序市场：市场规模、份额和趋势分析（按技术、产品、应用、工作流程和最终用途划分），细分市场预测（2025-2033 年）

U.S. Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology, By Product, By Application, By Workflow (Pre-sequencing, Sequencing, Data Analysis), By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国次世代定序市场摘要

据估计，美国次世代定序市场在 2024 年的价值为 37.6 亿美元，预计到 2033 年将达到 167.5 亿美元，2025 年至 2033 年的复合年增长率为 18.1%。

该国强大的製药、生物技术和研究机构正在推动次世代定序(NGS) 技术的发展。市场成长的驱动力来自不断增加的研发项目，这些项目主要集中在癌症、感染疾病和精准医疗领域。此外，基因检测技术的进步也促进了 NGS 在临床实验室中的应用，用于诊断罕见疾病和指南精准医疗。

癌症和遗传性疾病发生率不断上升

美国癌症、遗传性疾病和复杂遗传疾病的日益普遍是推动新一代定序（NGS）市场发展的关键因素。次世代定序能够早期检测基因突变和染色体异常，从而实现及时诊断和製定个人化治疗方案。在肿瘤学领域，NGS有助于识别肿瘤特异性突变，对患者进行分层以进行标靶治疗，并监测疾病进展和復发。它还能提供罕见疾病和遗传疾病的全面基因组信息，支持精准诊断、带因者筛检和家族风险评估。医护人员和病患对基因检测益处的认识不断提高，也进一步促进了NGS的普及应用。

此外，新生儿筛检计画、产前基因检测和大规模人群基因组学研究等措施正在推动NGS在临床和研究领域的应用。对精准医疗日益增长的需求以及对基因和基因组研究投入的增加，凸显了NGS在改善患者预后方面发挥的关键作用。随着癌症和遗传疾病发病率的持续上升，NGS的应用预计将稳步增长，从而巩固其作为美国医疗保健和生命科学生态系统中一项变革性技术的地位。

目录

第一章 分析方法和范围

第二章执行摘要

第三章美国次世代定序市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国次世代定序市场：分析工具
    • SWOT分析：依因素（政治、法律、经济、技术）进行分析
    • 波特五力分析

第四章美国次世代定序市场：按技术分類的业务分析

  • 按变异分析和技术分類的次世代定序市场
  • 标靶定序、定序
  • 全基因测序
  • 全EXOME定序

第五章美国次世代定序市场：按产品分類的业务分析

  • 次世代定序市场：产品差异分析
  • 平台
  • 消耗品

第六章美国次世代定序市场：按应用领域分類的业务分析

  • 次世代定序市场：应用变异分析
  • 瘤
  • 临床研究
  • 生殖健康
  • HLA型检测/免疫系统监测
  • 总体基因体学、流行病学和药物研发
  • 农业基因组学，法医学
  • 消费者基因体学

第七章美国次世代定序市场：依工作流程进行业务分析

  • 次世代定序市场：工作流程差异分析
  • 前序
  • 定序
  • 数据分析

第八章美国次世代定序市场：按最终用途分類的业务分析

  • 次世代定序市场：最终用途差异分析
  • 学术研究
  • 临床研究
  • 医院和诊所
  • 製药和生物技术公司
  • 其他用户

第九章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 市场情势分析（2024年）
  • 市场参与企业概览
    • Illumina, Inc
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • Eurofins Scientific SE
    • QIAGEN
    • Quest Diagnostics Incorporated
    • Azenta Life Sciences (GENEWIZ)
    • NanoString
    • PacBio
    • bioMerieux
    • BGI Group
    • F. Hoffmann-La Roche Ltd
    • ARUP Laboratories
    • Novogene Co, Ltd.
    • Gene by Gene Ltd.
    • Lucigen Corporation
Product Code: GVR-4-68040-218-3

U.S. Next Generation Sequencing Market Summary

The U.S. next generation sequencing market size was estimated at USD 3.76 billion in 2024 and is projected to reach USD 16.75 billion by 2033, growing at a CAGR of 18.1% from 2025 to 2033. A robust presence of pharmaceutical, biotech entities, and research institutions drives next-generation sequencing (NGS) technology in the country. The market is propelled by increasing research and development (R&D) programs focusing on cancer, infectious diseases, and precision medicine. Moreover, genetic testing advancements are fueling NGS adoption in clinical labs for diagnosing rare conditions and guiding precision medicine.

Rising Incidence of Cancer and Genetic Disorders

The increasing prevalence of cancer, hereditary diseases, and complex genetic disorders in the U.S. is a significant driver of the NGS market. Next-generation sequencing enables early detection of genetic mutations and chromosomal abnormalities, facilitating timely diagnosis and personalized treatment planning. In oncology, NGS helps identify tumor-specific mutations, stratify patients for targeted therapies, and monitor disease progression or recurrence. It provides comprehensive genomic insights for rare and inherited disorders, supporting accurate diagnosis, carrier screening, and risk assessment for family members. Growing awareness among healthcare providers and patients about the benefits of genetic testing is further fueling adoption.

Moreover, initiatives such as newborn screening programs, prenatal genetic testing, and large-scale population genomics studies are expanding the use of NGS across clinical and research settings. The increasing demand for precision medicine, coupled with rising investment in genetic and genomic research, underscores the critical role of NGS in improving patient outcomes. As the incidence of cancer and genetic disorders continues to increase, the adoption of NGS is expected to grow steadily, solidifying its position as a transformative technology in the U.S. healthcare and life sciences ecosystem.

U.S. Next Generation Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. next generation sequencing market based on technology, product, application, workflow, and end use.

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing
    • DNA-based
    • RNA-based
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Platforms
    • Sequencing
    • Data Analysis
  • Consumables
    • Sample Preparation
    • Target Enrichment
    • Others
  • Application Outlook (Revenue, USD Million; 2021 - 2033)
  • Oncology
    • Diagnostics and Screening
    • Oncology Screening
    • Sporadic Cancer
    • Inherited Cancer
    • Companion Diagnostics
    • Other Diagnostics
    • Research Studies
  • Clinical Investigation
    • Infectious Diseases
    • Inherited Diseases
    • Idiopathic Diseases
    • Non-Communicable/Other Diseases
  • Reproductive Health
    • NIPT
    • Aneuploidy
    • Microdeletions
    • PGT
    • Newborn Genetic Screening
    • Single Gene Analysis
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Agrigenomics & Forensics
  • Consumer Genomics
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Pre-Sequencing
    • Nucleic Acid Extraction
    • Library Preparation
  • Sequencing
  • NGS Data Analysis
    • NGS Primary Data Analysis
    • NGS Secondary Data Analysis
    • NGS Tertiary Data Analysis
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Other users

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Technology
    • 1.1.2. Product
    • 1.1.3. Application
    • 1.1.4. Workflow
    • 1.1.5. End-use
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights

Chapter 3. U.S. Next Generation Sequencing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer and genetic disorders
      • 3.2.1.2. Advancements in sequencing technologies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of computational efficiency for data management
      • 3.2.2.2. Non-value-based NGS reimbursement policy and regulation status
      • 3.2.2.3. Challenges associated with NGS implementation.
  • 3.3. U.S. Next Generation Sequencing Market Analysis Tools
    • 3.3.1. SWOT analysis; by factor (political & legal, economic, and technological)
    • 3.3.2. Porter's Five Forces Analysis

Chapter 4. U.S. Next Generation Sequencing Market: Technology Business Analysis

  • 4.1. Next Generation Sequencing Market: Technology Movement Analysis
  • 4.2. Targeted Sequencing & Resequencing
    • 4.2.1. Targeted Sequencing & Resequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 4.2.1.1. DNA-based targeted sequencing & resequencing
        • 4.2.1.1.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
      • 4.2.1.2. RNA-based targeted sequencing & resequencing
        • 4.2.1.2.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 5. U.S. Next Generation Sequencing Market: Product Business Analysis

  • 5.1. Next Generation Sequencing Market: Product Movement Analysis
  • 5.2. Platforms
    • 5.2.1. Platforms Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 5.2.1.1. Sequencing
        • 5.2.1.1.1. Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
      • 5.2.1.2. Data Analysis
        • 5.2.1.2.1. Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million
  • 5.3. Consumables
    • 5.3.1. Consumables market estimates and forecast, 2021 - 2033 (USD million)
    • 5.3.2. Sample Preparation
      • 5.3.2.1. Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
    • 5.3.3. Target Enrichment
      • 5.3.3.1. Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 6. U.S. Next Generation Sequencing Market: Application Business Analysis

  • 6.1. Next Generation Sequencing Market: Application Movement Analysis
  • 6.2. Oncology
    • 6.2.1. Oncology Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.2.2. Diagnostics & Screening
      • 6.2.2.1. Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.2. Oncology screening
        • 6.2.2.2.1. Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
        • 6.2.2.2.2. Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
        • 6.2.2.2.3. Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.3. Companion diagnostics
        • 6.2.2.3.1. Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.4. Other diagnostics
        • 6.2.2.4.1. Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.2.3. Research Studies
      • 6.2.3.1. Research studies market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3. Clinical investigation
    • 6.3.1. Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.2. Infectious Diseases
      • 6.3.2.1. Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.3. Idiopathic Diseases
      • 6.3.3.1. Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.4. Inherited Diseases
      • 6.3.4.1. Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.5. Non-Communicable/Other Diseases
      • 6.3.5.1. Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4. Reproductive Health
    • 6.4.1. Reproductive Health Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.4.2. NIPT
      • 6.4.2.1. NIPT market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.4.2.2. Aneuploidy
        • 6.4.2.2.1. Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.4.2.3. Microdeletions
        • 6.4.2.3.1. Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.3. PGT
      • 6.4.3.1. PGT market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.4. Newborn Genetic Screening
      • 6.4.4.1. Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.5. Single Gene Analysis
      • 6.4.5.1. Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5. HLA Typing/Immune System Monitoring
    • 6.5.1. HLA Typing/Immune System Monitoring Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.6. Metagenomics, Epidemiology & Drug Development
    • 6.6.1. Metagenomics, Epidemiology & Drug Development Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.7. Agrigenomics & Forensics
    • 6.7.1. Agrigenomics & Forensics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.8. Consumer Genomics
    • 6.8.1. Consumer Genomics Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 7. U.S. Next Generation Sequencing Market: Workflow Business Analysis

  • 7.1. Next Generation Sequencing Market: Workflow Movement Analysis
  • 7.2. Pre sequencing
    • 7.2.1. Pre-Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 7.2.1.1. Nucleic acid extraction
        • 7.2.1.1.1. Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
      • 7.2.1.2. Library preparation
        • 7.2.1.2.1. Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3. Sequencing
    • 7.3.1. Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.4. Data Analysis
    • 7.4.1. Data Analysis Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.4.2. Primary Data NGS Analysis
      • 7.4.2.1. Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.3. Secondary Data Analysis
      • 7.4.3.1. Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.4. Tertiary Data Analysis
      • 7.4.4.1. Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. U.S. Next Generation Sequencing Market: End Use Business Analysis

  • 8.1. Next Generation Sequencing Market: End-use Movement Analysis
  • 8.2. Academic Research
    • 8.2.1. Academic Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.3. Clinical Research
    • 8.3.1. Clinical Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.4. Hospitals & Clinics
    • 8.4.1. Hospitals & Clinics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.5. Pharmaceutical & Biotech Entities
    • 8.5.1. Pharmaceutical & Biotech Entities Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.6. Other Users
    • 8.6.1. Other Users Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Market position analysis, 2024
  • 9.4. Participants Overview
    • 9.4.1. Illumina, Inc
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Thermo Fisher Scientific Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Eurofins Scientific SE
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Eurofins Scientific SE
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. QIAGEN
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Quest Diagnostics Incorporated
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Azenta Life Sciences (GENEWIZ)
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. NanoString
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. PacBio
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. bioMerieux
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. BGI Group
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. F. Hoffmann-La Roche Ltd
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. ARUP Laboratories
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. Novogene Co, Ltd.
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. Gene by Gene Ltd.
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
      • 9.4.15.4. Strategic initiatives
    • 9.4.16. Lucigen Corporation
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. next generation sequencing market, by technology, 2021 - 2033 (USD Million)
  • Table 4 U.S. next generation sequencing market, by product, 2021 - 2033 (USD Million)
  • Table 5 U.S. next generation sequencing market, by application, 2021 - 2033 (USD Million)
  • Table 6 U.S. next generation sequencing market, by workflow, 2021 - 2033 (USD Million)
  • Table 7 U.S. next generation sequencing market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. next generation sequencing market: market outlook
  • Fig. 7 U.S. next generation sequencing competitive insights.
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook.
  • Fig. 10 Penetration and growth prospect mapping
  • Fig. 11 Industry value chain analysis
  • Fig. 12 U.S. next generation sequencing market driver impact
  • Fig. 13 U.S. next generation sequencing market restraint impact
  • Fig. 14 U.S. next generation sequencing market strategic initiatives analysis
  • Fig. 15 U.S. next generation sequencing market: Technology movement analysis
  • Fig. 16 U.S. next generation sequencing market: Technology outlook and key takeaways
  • Fig. 17 Targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Whole genome sequencing market estimates and forecast, 2021-2033 (USD Million)
  • Fig. 21 Whole exome sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. Next-generation sequencing market: Product outlook key takeaways
  • Fig. 23 U.S. Next-generation sequencing market: Product movement analysis
  • Fig. 24 Platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Consumables market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. next generation sequencing Market: Application Movement Analysis
  • Fig. 32 U.S. next generation sequencing market: Application outlook and key takeaways
  • Fig. 33 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Research studies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Reproductive health market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 NIPT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 49 Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 PGT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 HLA typing/immune system monitoring market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Metagenomics, epidemiology & drug development market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 55 Agrigenomics & forensics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Consumer genomics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 57 U.S. next generation sequencing market: workflow movement analysis
  • Fig. 58 U.S. next generation sequencing market: workflow outlook and key takeaways
  • Fig. 59 Pre-sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Automated library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 63 Sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 Data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 65 Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 67 Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 U.S. Next generation sequencing market End Use outlook key takeaways
  • Fig. 69 U.S. Next-generation sequencing market: End Use movement analysis
  • Fig. 70 Academic research market estimates and forecast, 2021 - 2033 (USD Million))
  • Fig. 71 Clinical research market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 72 Hospitals & clinics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 73 Pharmaceutical & biotech entities market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Other users market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 75 Market share of key market players- U.S. next generation sequencing market